“Innovate in India is anticipated as the game changer for biopharma industry”

In an exclusive interaction with the BioVoice News, the Managing Director of UBM India, Mr Yogesh Mudras shared his thoughts on the present scenario and future of pharma sector. Read the interesting interview below:

0
188
Download PDF

The UBM India is one of the country’s leading exhibition organiser that provides the industry with platforms for interaction such as conferences, exhibitions and seminars. In a recent interaction with the BioVoice, Mr Yogesh Mudras, Managing Director, UBM India provided the detailed insights into his company’s operations besides the current scenario and future of pharma sector and packaging industry. Read on: 

How do you look at the growth of the Indian bio-pharma sector in terms of size and scale over decades? What are the opportunities that still remain untapped?

India is playing an active role in the global pharmaceutical industry and has contributed towards making life-saving drugs and low cost pharmaceutical products accessible and affordable. Be it the Rotavirus vaccine, heart valve prosthesis or affordable insulin. However, despite these developments, the biopharmaceutical industry of India is lagging when compared with the developed countries and is facing tough competition from other countries. Recently in this year in June, the Government of India launched a program Innovate in India (i3) for the Indian biopharmaceutical industry which is anticipated as the game changer for the industry.

Currently, India has only 2.8 percent share in the global biopharmaceutical market and the new mission by the Government of India would elevate this to 5% resulting in an additional business opportunity of 16 Billion USD. Government is committed to make India a hub for development of affordable and effective biopharmaceutical products and aspires to create an enabling ecosystem to promote entrepreneurship and indigenous manufacturing in the sector with Innovate in India (i3) mission. Furthermore, it will also boost the growth curve for domestic biopharma in India by accelerating the translation of research concepts into viable products, supporting clinical validation, enabling sustainable networks for collaboration between industry and academia, and supporting entrepreneurial ecosystem amongst many others.

The pharmaceutical packaging industry has been an important allied sector to the pharma and biopharma sector. What are the latest trends in this industry?

Packaging is one market across the globe which is advancing at a constant pace in the pharmaceutical industry and is a critical part of delivery system in the sector that needs to be reliable and speedy and deliver a combination of quality, tamper evidence, patient comfort and protection. According to the industry forecasts, the global market is growing rapidly and is expected to reach $158.8 billion by 2025.

UBM India is playing a vital role in this space through their signature confex (conference and exhibition), Innopack. It is the biggest platform for Pharma Packaging professionals to congregate, network, exchange ideas and knowledge, form future alliances and shape the future of the pharma packaging industry, all under one roof. Participants benefit from subjects centred around innovations in pharmaceutical packaging to enhance sustainability, and simplify usage for patients through adopting latest technologies, including the future of 3D printing, advancements in Prefilled syringes, track and trace, serialization, packaging design and artwork.  The company through this confex, provides a platform to more than 6500 members of the pharmaceutical community from across the globe.

What are the major challenges (including technology and policy) before biopharma and packaging industries? What measures do you suggest to overcome these?

As biopharma moves from the scientific frontier to the business mainstream, the industry will increasingly be forced to confront the same challenges faced by other businesses, maintaining competitiveness by ensuring affordability, quality, and delivery performance. With highly competitive and time consuming approval process, the Indian biopharmaceutical ecosystem is facing issues like sub-optimal infrastructure, lack of funding avenues, little or no incentives and a shortage of highly skilled talent, among others. Governments in emerging markets understand the critical role that biopharma will play in boosting healthcare outcomes.

With regards to packaging in the pharma industry, global markets are flooded today with duplicate drugs posing a threat to the pharmaceutical industry. To tackle this biggest challenge faced by the pharma companies, various tools and solution providers have developed track and trace technology to fight counterfeiting. These tools also play an important role in the supply chain process and help in avoiding the security lapses and works to the advantage of pharma companies by stopping the illegal counterfeit of medicines. Another major issue which companies are facing in India as well as globally, is Serialization. It continues to be a driving force for change in the pharmaceutical packaging segment to fight counterfeiting, theft, diversion, and false returns to manufacturers. New serialized labelling technologies on display included printing 2D barcodes directly onto vials and onto pills and capsules. The effective serialization will cut down the counterfeiting of drugs in the supply chain.

What role has been the UBM playing in pushing the growth of the sector including future plans? How well received are your exhibitions and what have been the major milestones so far?

The role of B2B trade exhibitions is to upgrade, enhance, encourage and create solutions for the industry, UBM India is playing a very important role in the growth of the pharmaceutical industry through their flagship platform CPhI India and P-MEC for the industry. Every year, we introduce a new chapter to this expo which is South Asia’s leading Pharma meeting place covering every step of the supply chain, from drug discovery to finished dosage while P-MEC includes manufacturers of Pharma Machinery, Products and Packaging. The show is the epitome of India’s strength in the Pharma industry and has consistently grown to serve as an exclusive congregation of key global players across the pharmaceutical sector.

On CPhI India’s 10th Anniversary last year, we offered our attendees innovation par excellence with the launch of the India Pharma Week (IPW). A marquee event, the IPW celebrated and acknowledged the growth of Indian Pharma Industry, through a range of platforms to cater to various needs- business, leadership, knowledge, innovation, recognition and networking. A special White Paper Report on the Challenges of the Sector was also prepared basis on the discussions by top CEOS of pharma companies at the CEO Roundtable held during the IPW 2016 and was presented to the Prime Minister’s Office. CPhI and P-Mec India have attracted 50,000 attendees from 94 countries across the globe. Last year, the event witnessed a record participation of 1,087 exhibitors from 21 countries.

NO COMMENTS